PTPN1单倍剂量不足导致的自身炎症性脑病:病例系列研究
通过筛查I型干扰素信号上调的患者,识别出12例PTPN1杂合突变患者,表现为亚急性运动语言技能丧失、痉挛性肌张力障碍和延髓受累,脑脊液新蝶呤升高,干扰素刺激基因上调,部分患者对高剂量皮质类固醇有临床改善。
要点
- PTPN1杂合突变导致I型干扰素驱动的自身炎症性脑病,表现为亚急性运动语言技能丧失、痉挛性肌张力障碍和延髓受累。
- 所有受检患者脑脊液新蝶呤升高,全血干扰素刺激基因上调。
- 八例治疗患者中六例经高剂量皮质类固醇临床判断神经状态改善,但部分未治疗患者也见稳定或恢复。
核心结论
- PTPN1单倍剂量不足导致I型干扰素驱动的自身炎症性脑病。
- 部分患者未经治疗也可出现神经功能稳定甚至恢复,而另一些患者对免疫抑制治疗有反应。
- 需要前瞻性研究来探究特定免疫抑制方法在该疾病人群中的安全性和有效性。
研究设计与样本
- 病例系列研究,通过欧洲(捷克、法国、德国、意大利、斯洛文尼亚、英国)和以色列的儿科神经病学和临床遗传学合作识别患者。
- 通过外显子组和定向Sanger测序鉴定PTPN1变异,通过定量PCR或NanoString技术检测干扰素刺激基因表达。
- 在患者成纤维细胞、hTERT永生化BJ-5ta成纤维细胞和RPE-1细胞中使用CRISPR-Cas9编辑和标准细胞生物学技术进行实验。
主要发现
- 2013年12月20日至2023年1月11日期间,从11个家庭中识别出12例PTPN1杂合突变患者。
- 发现10个新发或极罕见PTPN1变异(gnomAD版本4.1.0频率<1·25 × 10^-6),其中6个预测为STOP突变,2个涉及经典剪接位点核苷酸,2个为错义替换。
- 3例患者变异为新发,9例遗传自无症状父母。
- 临床表型特征为亚急性起病(年龄范围1-8岁)的运动和语言技能丧失,无癫痫发作,初期发育正常,导致痉挛性肌张力障碍和延髓受累。
- 神经影像学显示脑萎缩(有时初期单侧)或T2白质高信号。
临床怎么用
- 原文未据此给出推荐。
局限性
- 需要前瞻性研究来探究特定免疫抑制方法在该疾病人群中的安全性和有效性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Through the agnostic screening of patients with uncharacterised disease phenotypes for an upregulation of type I interferon (IFN) signalling, we identified a cohort of individuals heterozygous for mutations in PTPN1, encoding the protein-tyrosine phosphatase 1B (PTP1B). We aimed to describe the clinical phenotype and molecular and cellular pathology of this new disease. METHODS: In this case series, we identified patients and collected clinical and neuroradiological data through collaboration with paediatric neurology and clinical genetics colleagues across Europe (Czechia, France, Germany, Italy, Slovenia, and the UK) and Israel. Variants in PTPN1 were identified by exome and directed Sanger sequencing. The expression of IFN-stimulated genes was determined by quantitative (q) PCR or NanoString technology. Experiments to assess RNA and protein expression and to investigate type 1 IFN signalling were undertaken in patient fibroblasts, hTERT-immortalised BJ-5ta fibroblasts, and RPE-1 cells using CRISPR-Cas9 editing and standard cell biology techniques. FINDINGS: Between Dec 20, 2013, and Jan 11, 2023, we identified 12 patients from 11 families who were heterozygous for mutations in PTPN1. We found ten novel or very rare variants in PTPN1 (frequency on gnomAD version 4.1.0 of <1·25 × 10:sup>-6). Six variants were predicted as STOP mutations, two involved canonical splice-site nucleotides, and two were missense substitutions. In three patients, the variant occurred de novo, whereas in nine affected individuals, the variant was inherited from an asymptomatic parent. The clinical phenotype was characterised by the subacute onset (age range 1-8 years) of loss of motor and language skills in the absence of seizures after initially normal development, leading to spastic dystonia and bulbar involvement. Neuroimaging variably demonstrated cerebral atrophy (sometimes unilateral initially) or high T2 white matter signal. Neopterin in CSF was elevated in all ten patients who were tested, and all probands demonstrated an upregulation of IFN-stimulated genes in whole blood. Although clinical stabilisation and neuroradiological improvement was seen in both treated and untreated patients, in six of eight treated patients, high-dose corticosteroids were judged clinically to result in an improvement in neurological status. Of the four asymptomatic parents tested, IFN signalling in blood was normal (three patients) or minimally elevated (one patient). Analysis of patient blood and fibroblasts showed that tested PTPN1 variants led to reduced levels of PTPN1 mRNA and PTP1B protein, and in-vitro assays demonstrated that loss of PTP1B function was associated with impaired negative regulation of type 1 IFN signalling. INTERPRETATION: PTPN1 haploinsufficiency causes a type 1 IFN-driven autoinflammatory encephalopathy. Notably, some patients demonstrated stabilisation, and even recovery, of neurological function in the absence of treatment, whereas in others, the disease appeared to be responsive to immune suppression. Prospective studies are needed to investigate the safety and efficacy of specific immune suppression approaches in this disease population. FUNDING: The UK Medical Research Council, the European Research Council, and the Agence Nationale de la Recherche.
引用
- Zhu G, Didry-Barca B, Seabra L, et al. Autoinflammatory encephalopathy due to PTPN1 haploinsufficiency: a case series. Lancet Neurol. 2025. PMID: 39986310. doi:10.1016/S1474-4422(24)00526-X
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。